Herbert Loong: Promising data on D3S-001 at AACR25
Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO), reshared a post by Cheng Chen, Senior Medical Director at D3 Bio, on LinkedIn, adding:
“Thank you Cheng Chen and colleagues at D3 Bio together with my fellow co-investigators for giving me the opportunity to present our promising data at AACR.
D3S-001 is a novel next generation KRASG12C inhibitor with efficient and rapid target engagement which may holds promise for improved efficacy and prolonged response compared with 1st generation inhibitors.
Our trials are on-going and we look forward to read out of these results in coming days.”
Quoting Cheng Chen‘s post:
“Thrilled to share our AACR oral presentation and simultaneous Nature Medicine publication! Honored to be a co-author.
Heartfelt thanks to all investigators, site staff, patients, their families, and our amazing D3 Bio colleagues as sponsor!
This milestone drives us to do great things for patients worldwide!”
Herbert Loong shared data from a clinical trial of D3S-001, a next-generation KRASG12C inhibitor, emphasizing its potential for better efficacy and response durability compared to earlier inhibitors. The results were presented at AACR and published in Nature Medicine, highlighting collaboration across research teams.
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial.
Journal: Nature Medicine
Authors: Byoung Chul Cho, et al.
More posts featuring Herbert Loong.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023